Citius Oncology, INC 8-K filings

Citius Oncology has reached an agreement with Dr. Reddy's for a partial deferral of a milestone payment due on September 9, 2024, related to the regulatory approval of LYMPHIRTM.

Citius Pharmaceuticals and Citius Oncology announce that LYMPHIR has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for the treatment of Cutaneous T-cell Lymphoma (CTCL).

Citius Oncology, formerly TenX Keane Acquisition, has completed its business combination with Citius Oncology Sub, Inc. and amended its financial disclosures to reflect the transaction.

Citius Oncology, Inc. has finalized its business combination with TenX Keane Acquisition, marking its debut on the Nasdaq Capital Market under the ticker symbol CTOR.

TenX Keane Acquisition shareholders approved a business combination with Citius Oncology and a new stock incentive plan at an extraordinary general meeting on August 2, 2024.

TenX Keane Acquisition received a $66,667 promissory note from Citius Pharmaceuticals to extend the deadline for their business combination by one month.

TenX Keane Acquisition received a $66,667 deposit from Citius Pharma, extending the deadline for their business combination to July 18, 2024.

TenX Keane Acquisition made additional payments to shareholders who redeemed their shares, correcting an initial miscalculation of the redemption price.

TenX Keane Acquisition extended its deadline to complete a business combination to June 18, 2024, by securing a $66,667 deposit from Citius Pharma.

TenX Keane Acquisition secured a one-month extension to complete its business combination by receiving a $66,667 deposit from Citius Pharmaceuticals.

TenX Keane Acquisition received a $200,000 loan from Citius Pharmaceuticals to extend its business combination deadline to April 18, 2024, following shareholder approval.